Group 1 - The company, Tianjin Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Tianjin Drug Administration for its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd. [1] - The inspection was conducted from November 25 to November 28, 2025, focusing on the production line for hormone eye drops [1][2] - The inspection concluded that the production line meets the requirements of the 2010 revised Good Manufacturing Practice (GMP) [2] Group 2 - The production line is the company's first for hormone eye drops, indicating that the company now has the capability to produce these products [2] - This development is expected to better meet market demand and ensure the supply of medications [2] - However, the actual sales performance post-production may be influenced by market environment changes, introducing a level of uncertainty [2]